recall
saveLEO PHARMA INC recall (Cls II)
community read0 votes
Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO Pharma Inc., Madison, NJ 07940, USA, — Reason: Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber. — Status: Ongoing
view source ↗Data sources
last refreshed 28m ago
Found something off?
same company · ±60 days · 6
- device pmaMedinol, Ltd. — EluNIR Ridaforolimus Eluting Coronary Stent System (PMA supplement)Mar 26, 2026
- device pmaMedinol, Ltd. — EluNIR Ridaforolimus Eluting Coronary Stent System (PMA supplement)Feb 4, 2026
- approvalBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalApr 15, 2026
- approvalBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalApr 15, 2026
- recallGOLD STAR DISTRIBUTION INC recall (Cls II)Jan 21, 2026
- approvalBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalApr 15, 2026
comments(0)
5-min edit window · permanent after that